You are about to leave the Nuvalent website.

Nuvalent does not endorse or take responsibility for any information or statements made on external sites.

Do you wish to continue?

Our Team

Emily Drabant Conley, PhD

Dr. Emily Drabant Conley is a strategic biotech executive with a proven track record of advancing disruptive platforms in drug development. She joined the Nuvalent board in February 2022. In addition to Nuvalent, Dr. Conley serves on the boards of Federation Bio, TMRW and Medrio and formerly served on the boards of Lesbians Who Tech and the UCSF Alliance Health Project.

Dr. Conley is Chief Executive Officer of Federation Bio, a biotechnology company pioneering engineered bacterial cell therapies. The company’s first-in-class platform is advancing programs in immuno-oncology and metabolic diseases.

Before her role at Federation Bio, Dr. Conley spent over a decade at 23andMe, where she helped scale the company from 30 employees into the world’s leading platform for genetic-driven drug discovery. As Vice President of Business Development at 23andMe, she architected visionary partnerships across pharma and biotech. ​

Dr. Conley has received numerous awards and honors, including Endpoints 20 Biopharma Leaders Under 40, Business Insider’s 30 Biotech Leaders Under 40, and Google Ventures 25 Women shaping the future of Technology.

Prior to industry, Dr. Conley was a research fellow at the National Institutes of Health and is co-author on more than 35 academic publications. She received her Ph.D. in Neuroscience from Stanford University School of Medicine, where she held fellowships from the National Science Foundation and Department of Defense. She graduated summa cum laude from Vanderbilt University with a B.A.